Tay-Sachs and a HEXA Carrier Result: What One Variant Really Means

Tay-Sachs and a HEXA Carrier Result: What One Variant Really Means

This article is for educational purposes only. It is not a substitute for advice from a licensed physician, board-certified medical geneticist, or board-certified genetic counselor. For any decisions about testing, treatment, or care, consult a qualified clinician. In emergencies, call 911.

Bottom line: Decades of genetic and public-health evidence show that Tay-Sachs disease is an autosomal recessive single-gene disorder of the HEXA gene. It appears only when a child inherits two altered copies. Carrying one HEXA variant, as a 23andMe report may flag, makes you a healthy carrier, not a patient. The same body of research explains why community carrier screening has been such a public-health success.

What you’ll learn

• Why one HEXA variant makes you a carrier, not a person with Tay-Sachs.
• The exact recurrence-risk numbers if your reproductive partner is also a carrier.
• How US and Canada testing works, from enzyme assays to consumer panels.
• The honest current treatment status, including where the 2025 gene-therapy trial stands.

How Tay-Sachs Is Inherited: The HEXA Gene and Autosomal Recessive Transmission

Tay-Sachs disease is caused by changes in a single gene called HEXA, located on chromosome 15. This gene carries the recipe for one part of an enzyme, the alpha subunit of beta-hexosaminidase A. Think of that enzyme as a tiny recycling machine inside cells. When it works, it breaks down a fatty substance in nerve cells. When two copies of the gene fail, that machine goes quiet. That one simple job, done or not done, sits at the center of everything else here.

Tay-Sachs follows autosomal recessive inheritance. That phrase means a person needs two altered copies of the gene, one from each parent, before the disorder appears. Everyone carries two copies of HEXA. A carrier has one working copy and one non-working copy. The single working copy makes enough enzyme, so a carrier stays healthy and shows no symptoms. Picture a two-burner stove where only one burner lights: it still cooks the meal, just with less capacity to spare.

An affected child is different. That child inherits one non-working copy from each parent. With no working copy, the fatty substance called GM2 ganglioside builds up in nerve cells and slowly damages the brain. The harm is not because that substance is a poison in normal amounts. It is a routine part of nerve-cell membranes. The harm comes from the body being unable to clear the excess. This is why a single carrier is at zero personal risk, a point the next sections make concrete.

Researchers who catalog the HEXA gene have documented well over a hundred distinct variants. In people of Ashkenazi (eastern and central European) Jewish heritage, a few founder variants are especially common. These include a four-base insertion in exon 11, written as 1278insTATC, and a splice-junction change near intron 12. There is also a “pseudodeficiency allele,” a quirk that can lower enzyme readings without causing disease. That quirk matters for testing, and a later section returns to it.

One practical caution applies to consumer reports. A 23andMe carrier report typically tests only a limited panel of the most common HEXA variants. So a negative report does not fully rule out carrier status, especially in people who are not of Ashkenazi ancestry. If your family history or a clinician’s concern points toward Tay-Sachs, a broader clinical test is the right tool, not a consumer panel. A board-certified genetic counselor, found through the National Society of Genetic Counselors at NSGC.org, can explain which test fits your situation.

Section recap: Tay-Sachs comes from two altered copies of the HEXA gene, so a single-variant carrier stays healthy. Over a hundred known variants exist, including Ashkenazi founder alleles and a pseudodeficiency quirk that complicates testing.

Risk Magnitude: Carrier Frequency, Absolute Recurrence Risk, and Penetrance

Genetics can feel abstract, so it helps to turn the odds into plain counts. The key rule comes from recessive inheritance. If both reproductive partners are HEXA carriers, each pregnancy carries fixed probabilities. There is a 25% chance the child inherits two altered copies and is affected. There is a 50% chance the child is a carrier like the parents. There is a 25% chance the child inherits two working copies and is neither.

Translated to counts, imagine 100 pregnancies between two carrier parents. On average, the outcomes break down like this:

• About 25 out of 100 children would have Tay-Sachs (two altered copies).
• About 50 out of 100 would be healthy carriers (one altered copy), just like their parents.
• About 25 out of 100 would carry no variant at all (two working copies).

These are averages across many pregnancies, not a schedule. A common misread is to assume that once a carrier couple has one affected child, the “next three are safe.” That is not how it works. Each individual pregnancy still faces the same independent 1-in-4 chance, the same way each coin flip stays 50-50 no matter what came before.

Now consider a single carrier, like a reader who saw one HEXA flag on a 23andMe report. Being a carrier means your own risk of having Tay-Sachs is essentially zero, because you have a working copy. Recurrence risk only becomes relevant if your reproductive partner is also a HEXA carrier. In other words, your result is a piece of family-planning information, not a personal diagnosis. It tells you something you might act on before a pregnancy, not something you need to treat in yourself.

How common is carrier status in the first place? The frequency depends heavily on ancestry, and primary sources put concrete numbers on it:

Population	Approximate carrier frequency	Source
Ashkenazi Jewish	About 1 in 27 to 1 in 30
French-Canadian (Quebec), Cajun (Louisiana), Old Order Amish (Pennsylvania)	Founder variants at comparable or higher frequency
General (non-Jewish) population	About 1 in 250 to 1 in 300

These figures are not a judgment about any group; they are simply the founder-population genetics that research has documented. They explain why screening programs first focused on higher-frequency communities, and why partner testing matters most when one partner has Ashkenazi, French-Canadian, Cajun, or Amish heritage.

Tay-Sachs also behaves differently from many gene results people worry about. When a child inherits two pathogenic HEXA variants, the disease has near-complete penetrance, meaning the effect reliably follows. Penetrance is simply how often a gene result actually produces its effect. Many consumer-test findings carry low, fuzzy penetrance, a mere “increased risk.” Tay-Sachs in an affected child is the opposite: near-certain, which is exactly why community carrier screening exists. A genetic counselor can put your own numbers in context.

Section recap: For two carrier parents, each pregnancy has a 25% chance of an affected child, so about 25 of 100. A single carrier faces essentially zero personal risk, and carrier frequency is far higher in Ashkenazi and certain founder populations.

The Biology: HEXA, Hex-A Deficiency, and GM2 Ganglioside Buildup

Understanding why the enzyme matters removes a lot of confusion. Pathogenic HEXA variants reduce or eliminate a working enzyme called beta-hexosaminidase A, often shortened to Hex-A. This enzyme lives inside lysosomes, the recycling compartments of cells. Its normal job is to break down GM2 ganglioside, a fatty substance found in nerve-cell membranes. Think of Hex-A as the disposal unit in a sink: when it runs, waste clears; when it fails, waste piles up.

Without enough Hex-A, GM2 ganglioside gradually accumulates inside neurons, especially in the brain and retina. That buildup drives the progressive nerve damage that defines the disease. The retina involvement is why clinicians describe a characteristic “cherry-red spot” in the infantile form, seen during an eye exam. This is medical detail best interpreted by a specialist, not read off a chart at home.

How much enzyme survives shapes which form of the disease appears. Research describes a continuum tied to residual Hex-A activity:

Form	Residual Hex-A activity	Typical onset and features
Infantile (classic)	Near-absent	Onset about 3-6 months; developmental regression, cherry-red retinal spot, exaggerated startle response
Juvenile (subacute)	Very low	Onset roughly ages 2-5, slower progression
Late-onset (adult)	Partial	Onset in older teens or adulthood; milder, slowly progressive neurological features

This same biology explains the reassuring part. A carrier keeps roughly half-normal enzyme activity, which is plenty to clear GM2 ganglioside normally. That is why a carrier has no symptoms and no personal disease risk. The difference between “carrier” and “affected” is not a small gradient; it is the gap between one working copy and none. If any of these features apply to a family member, a pediatric neurologist or medical geneticist is the right person to consult.

Section recap: Pathogenic HEXA variants lower Hex-A, so GM2 ganglioside builds up in neurons and damages the brain. Residual enzyme level sets the infantile, juvenile, or late-onset form, while carriers keep enough enzyme to stay healthy.

Testing Options: Enzyme Assay, Molecular HEXA Testing, and DTC Reports

A US or Canada reader meets Tay-Sachs testing in several different settings, and sorting them out prevents needless worry. They are not interchangeable: one measures enzyme function, one reads the gene directly, and one is a limited consumer screen. The table below lays them side by side.

Testing setting	What it checks	Strengths and cautions	Diagnostic?
Hex-A enzyme-activity assay	Percentage of functional enzyme in serum or white blood cells	Longstanding carrier screen; pregnancy, oral contraceptives, and pseudodeficiency alleles can confound serum results, so leukocyte assay or molecular follow-up is used	Supports diagnosis with clinical picture
Molecular HEXA testing	Specific HEXA variants, via targeted panels or full-gene sequencing	Performed in CLIA-certified labs (Invitae, Labcorp, Quest and others); resolves the pseudodeficiency problem	Yes, when paired with enzyme and clinical findings
Direct-to-consumer report (23andMe)	A limited panel of common variants	Not diagnostic; a negative report cannot rule out carrier status, especially in non-Ashkenazi ancestry	No — confirm concerning results clinically

The enzyme assay is the classic approach. It measures how much functional Hex-A a person makes, and a low level flags a possible carrier or affected state. It has a well-known catch: the pseudodeficiency allele can lower the reading without causing any disease risk, and pregnancy or oral contraceptives can skew a serum result. For those reasons, a leukocyte (white-blood-cell) assay or molecular follow-up is often used to sort out an ambiguous result.

Molecular HEXA testing reads the gene itself. Targeted variant panels or full-gene sequencing, run in CLIA-certified laboratories, identify the specific pathogenic variants a person carries. Because it looks at the DNA rather than the enzyme, it sidesteps the pseudodeficiency confusion and is recommended alongside or instead of enzyme testing. This is often the tool that turns an uncertain enzyme result into a clear answer.

Consumer reports sit in a third category. The 23andMe carrier-status product tests only a limited set of common variants and is explicitly not diagnostic. A positive consumer flag is a reason to ask questions, not a diagnosis of anything. Treating a single carrier line as a verdict is like reading one page of a report and assuming you know the ending. Professional guidance also matters here: ACOG and ACMG support offering Tay-Sachs carrier screening within expanded, pan-ethnic panels, not only for those reporting Ashkenazi ancestry. Your obstetrician, primary care physician, or a genetic counselor at NSGC.org can arrange the right test.

Section recap: The Hex-A enzyme assay and molecular HEXA testing are the clinical tools, and molecular testing resolves the pseudodeficiency problem. Consumer panels are limited and not diagnostic, so confirm concerning results in a clinical lab.

Interpreting Your Result: Carrier vs Affected vs Variant of Uncertain Significance

Test results come in categories, and mixing them up is the main source of panic. An affected diagnosis requires two things together: two pathogenic HEXA variants and deficient Hex-A activity, alongside clinical features. That combination, not a single line on a report, defines the condition. A carrier finding is different. It means one pathogenic variant in an unaffected person, and its meaning is reproductive, not personal. Keeping these buckets straight removes most of the fear:

• Affected (Tay-Sachs) — two pathogenic HEXA variants plus deficient Hex-A activity and clinical features. This is the actual condition.
• Carrier — one pathogenic HEXA variant in a healthy person. Relevant to future children, not to your own health.
• Variant of uncertain significance (VUS) — a change the lab cannot yet call harmful or harmless. It is a “not enough evidence yet” label, not bad news.
• Pseudodeficiency finding — a lower enzyme reading that does not mean disease risk to offspring, resolved by molecular testing.

That VUS category confuses many readers. Professional standards from the American College of Medical Genetics and Genomics and the Association for Molecular Pathology set the rules for classifying variants. They sort variants into five tiers:

Classification	Plain meaning
Pathogenic	Known to cause the condition
Likely pathogenic	Strong evidence it is harmful, not yet certain
Uncertain (VUS)	Not enough evidence to call either way
Likely benign	Strong evidence it is harmless
Benign	Known to be harmless

A useful analogy is a weather forecast. “Pathogenic” is a confirmed storm warning, “benign” is a clear day, and a VUS is a forecast the meteorologists are still debating. You would not evacuate on a debated forecast, and you should not assume the worst from a VUS. Labs report the tier precisely so you and your clinician can judge how solid the finding is, and a VUS may be reclassified later as more data arrive.

For a reader with a single carrier result on a consumer panel, the reassuring reading is straightforward. One pathogenic HEXA variant means you are healthy and simply a carrier. The actionable next step is understanding your partner’s HEXA status, not tracking personal disease risk. If any consumer result concerns you, confirm it through a clinical genetics evaluation with a board-certified genetic counselor rather than acting on the raw report.

Section recap: An affected diagnosis needs two pathogenic variants plus deficient enzyme activity; one variant is a healthy carrier finding. A VUS is unclassified and a pseudodeficiency finding is not a disease risk, so confirm concerning results clinically.

Current Care and the Gene-Therapy Research Status

Here honesty matters most. There is no approved disease-modifying or curative therapy for Tay-Sachs disease as of 2026. Standard care is supportive and symptomatic. That means managing feeding, seizures, respiratory infections, and comfort, and supporting the family, usually coordinated through pediatric neurology and palliative care. Disease-specific nonprofits such as the National Tay-Sachs & Allied Diseases Association (NTSAD) also provide clinical and family-support resources. This section is not a treatment plan; a specialist must lead any care.

Research is active, and it deserves accurate framing rather than hype. A dual-vector gene-therapy trial has drawn attention, and here is what the primary evidence actually says:

• What it is: AXO-AAV-GM2 is a dual, co-administered AAVrh8 gene therapy (rAAVrh8-HEXA plus rAAVrh8-HEXB), given by combined brain and spinal-fluid delivery, intended to restore hexosaminidase activity in the central nervous system.
• The trial: The phase 1/2 study, registered as NCT04669535, enrolled nine children with Tay-Sachs and Sandhoff disease, six with the infantile form and three with the juvenile form.
• The findings: The work, published in Nature Medicine in 2025 by Eichler and colleagues, reported dose-dependent biochemical correction, with infantile patients showing global clinical stabilization and later, fewer, less severe seizures; worsening dystonia in juvenile patients led to their exclusion from further enrollment.
• The status: This is early-phase investigational research. The therapy is not approved by the FDA or Health Canada; the FDA has granted only Fast Track designation, and durable clinical benefit remains under study.

The honest summary is that these are encouraging biochemical signals in a very small trial, not an available treatment. A headline that calls this a “cure” would be wrong. Substrate-reduction and other approaches also remain experimental, with no approval. Any family facing Tay-Sachs should discuss current supportive care and possible trial eligibility with a specialist, rather than relying on news coverage. A metabolic or neurogenetics clinic can explain what is genuinely available today.

Section recap: No disease-modifying therapy is approved; care is supportive and symptomatic. The AXO-AAV-GM2 trial (NCT04669535, Nature Medicine 2025) showed early biochemical correction but is investigational and not FDA- or Health-Canada-approved.

Family Implications: Partner Testing and Cascade Carrier Screening

Because Tay-Sachs is recessive, one carrier result ripples through a family in a predictable way. Clinicians call the follow-up process cascade testing: checking relatives once a variant is known. Each full sibling of a carrier has a 50% chance of also being a carrier, since siblings share parents. That figure is a starting point for deciding who might want testing, not a cause for alarm.

For a reader thinking about future children, the most actionable step is clear: learn your reproductive partner’s HEXA carrier status. This matters most when a partner has Ashkenazi, French-Canadian, Cajun, or Amish heritage, where carrier frequency reaches roughly 1 in 27 to 30. The two possible outcomes lead to very different paths:

• Partner is not a carrier — your children cannot inherit two variants from the two of you, so they cannot have Tay-Sachs from this pairing.
• Partner is also a carrier — the 25% per-pregnancy figure from earlier applies, and further planning options open up.

That single test result is the pivot point for everything that follows, which is why counselors treat partner testing as the first practical move rather than testing every relative at once.

US and Canada couples have several evidence-supported paths. Expanded carrier screening before pregnancy can identify carrier couples early. For couples known to both carry a HEXA variant, more options open up, including:

• Prenatal diagnosis during a pregnancy, using chorionic villus sampling (CVS) or amniocentesis with enzyme or molecular testing.
• Preimplantation genetic testing for monogenic conditions (PGT-M), used with in vitro fertilization to select unaffected embryos.
• Expanded carrier screening for the couple before conception, so choices are made with full information.

Professional carrier-screening statements from ACOG and ACMG frame these choices. Long-running community programs, such as the Dor Yeshorim model in some Ashkenazi communities, are part of this history. A simple analogy helps: cascade testing is like tracing a shared family recipe. Once you know one relative has a particular ingredient, it is worth asking who else might. A board-certified genetic counselor at NSGC.org can map which relatives could benefit from testing, and in what order, without pressure.

Section recap: Each sibling of a carrier has a 50% chance of also carrying a variant, so partner testing is the key next step. Carrier couples can consider expanded screening, prenatal diagnosis, and PGT-M with counselor guidance.

Psychosocial and Legal Context: GINA, Insurance Gaps, and Disclosure to Relatives

Worry about insurance and about telling relatives is common and reasonable. US law offers real, but partial, protection. The Genetic Information Nondiscrimination Act of 2008, known as GINA, bars health insurers and employers from using genetic information in coverage, premium, underwriting, or employment decisions. That covers the two areas most people ask about first. But the coverage has a clear edge, and knowing where it stops is the whole point:

Protected by US GINA	Not protected by US GINA
Health insurance (coverage, premiums, underwriting)	Life insurance
Employment decisions (hiring, firing, pay, promotion)	Disability insurance
—	Long-term-care insurance

The gap is important to know before you apply for anything. GINA does not cover life, disability, or long-term-care insurance. Insurers in those categories may use genetic information for their decisions unless a stronger state law applies. So a reader weighing a life-insurance application, especially someone who works in the insurance industry, may want to understand this gap and possibly speak with a counselor before testing or disclosing. This is educational context, not legal advice.

Canada’s framework is broader. The Genetic Non-Discrimination Act became law in 2017. It criminalizes requiring or using genetic-test results as a condition of providing goods, services, or contracts, and that explicitly includes insurance contracts. On July 10, 2020, the Supreme Court of Canada upheld the Act as a valid exercise of Parliament’s criminal-law power. A Canadian reader therefore has stronger statutory footing than a US reader. The practical upshot is worth stating plainly:

• In the US, life, disability, and long-term-care insurers may consider genetic information unless a stronger state law applies.
• In Canada, the 2017 Act blocks compelling or using genetic-test results as a condition of goods, services, or contracts, including insurance.

Disclosure to relatives has an emotional side too. Telling a sibling that you carry a HEXA variant can feel awkward, yet it gives them useful reproductive information, since each has a 50% chance of also carrying it. Framing the conversation as a helpful heads-up, rather than bad news, often lands better. Many people find it easier to share the recurrence math than the label, since “here is a number that might matter for your family planning” feels less like an accusation and more like a gift. A board-certified genetic counselor at NSGC.org can help plan what to say and to whom, and can navigate the insurance-timing questions. For anything legal, consult a qualified professional, and for care decisions, consult a clinician.

Section recap: US GINA protects health coverage and employment but not life, disability, or long-term-care insurance; Canada’s 2017 law is broader. A genetic counselor can help with both disclosure and the insurance gap.

Frequently Asked Questions

Does a HEXA carrier flag on 23andMe mean the reader has Tay-Sachs? No. A single HEXA variant makes a person a healthy, unaffected carrier, because the other copy of the gene still works. Tay-Sachs requires two pathogenic copies plus deficient Hex-A enzyme activity. If the result is concerning, a genetic counselor can confirm and explain it.

Will the reader’s children inherit Tay-Sachs because one parent is a carrier? Only if the reproductive partner is also a HEXA carrier. In that case, each pregnancy carries a 25% chance of an affected child, so about 25 out of 100. Partner carrier testing is the key next step, and a counselor can arrange it.

Does an Ashkenazi Jewish partner change the odds? Yes. Ashkenazi Jewish heritage, and French-Canadian, Cajun, or Old Order Amish heritage, carries a higher carrier frequency of about 1 in 27 to 30. That makes partner carrier screening especially worthwhile before a pregnancy.

Is there a cure or approved treatment for Tay-Sachs now? No approved disease-modifying therapy exists as of 2026; care is supportive and symptomatic. A phase 1/2 gene-therapy trial (NCT04669535) reported early biochemical correction in Nature Medicine in 2025, but it is investigational and not FDA- or Health-Canada-approved.

Will a genetic result affect the reader’s life or health insurance? In the US, GINA protects health insurance and employment but not life, disability, or long-term-care insurance. In Canada, the 2017 Genetic Non-Discrimination Act offers broader protection, upheld by the Supreme Court in 2020. Understanding the gap before applying is wise.

Summary

The research is consistent and reassuring for a worried carrier. Tay-Sachs is an autosomal recessive disorder of the single HEXA gene, so a person needs two altered copies to be affected. Carrying one variant, as a 23andMe report may flag, makes you a healthy carrier, and your own risk of the condition is essentially zero. Recurrence risk only enters the picture if your reproductive partner is also a carrier, in which case each pregnancy has a 25% chance of an affected child. Everything else in your plan flows from that one partner-status question.

The practical path is clear. Enzyme and molecular HEXA testing in clinical labs sort out carrier status, and molecular testing resolves the pseudodeficiency confusion that can trip up enzyme-only results. On treatment, the honest picture is that no disease-modifying therapy is approved; care is supportive, and the 2025 AXO-AAV-GM2 trial is early investigational research, not an available cure. For your family, the most useful next steps are partner testing and a conversation with a board-certified genetic counselor at NSGC.org. It also helps to know the legal picture: in the US, GINA protects health coverage but not life insurance, while Canada’s law is broader.

This article is for educational purposes only. It is not a substitute for advice from a licensed physician, board-certified medical geneticist, or board-certified genetic counselor. For any decisions about testing, treatment, or care, consult a qualified clinician. In emergencies, call 911.

References

1. NIH / MedlinePlus Genetics. Tay-Sachs disease — MedlinePlus Genetics. National Library of Medicine. https://medlineplus.gov/genetics/condition/tay-sachs-disease/
2. Toro, Shao et al. HEXA Disorders (includes Tay-Sachs disease) — GeneReviews. NCBI Bookshelf, University of Washington. https://www.ncbi.nlm.nih.gov/books/NBK1218/
3. OMIM #272800. Tay-Sachs Disease; TSD — OMIM Entry #272800. Johns Hopkins University. https://www.omim.org/entry/272800
4. NHGRI / genome.gov. About Tay-Sachs Disease. National Human Genome Research Institute. https://www.genome.gov/Genetic-Disorders/Tay-Sachs-Disease
5. Eichler et al. (2025). Dual-vector rAAVrh8 gene therapy for GM2 gangliosidosis: a phase 1/2 trial. Nature Medicine, 31:2927-2935. https://www.nature.com/articles/s41591-025-03822-4
6. ClinicalTrials.gov. AXO-AAV-GM2 Gene Transfer for GM2 Gangliosidosis — NCT04669535. U.S. National Library of Medicine. https://clinicaltrials.gov/study/NCT04669535
7. ACOG (2017, reaffirmed). Carrier Screening for Genetic Conditions — Committee Opinion No. 691. American College of Obstetricians and Gynecologists. https://www.acog.org/clinical/clinical-guidance/committee-opinion/articles/2017/03/carrier-screening-for-genetic-conditions
8. Richards et al. (2015). Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the ACMG and AMP. Genetics in Medicine, 17:405-424. https://pmc.ncbi.nlm.nih.gov/articles/PMC4544753/
9. NHGRI / genome.gov. Genetic Discrimination and the Genetic Information Nondiscrimination Act (GINA). National Human Genome Research Institute. https://www.genome.gov/about-genomics/policy-issues/Genetic-Discrimination
10. Supreme Court of Canada (2020). Reference re Genetic Non-Discrimination Act, 2020 SCC 17; Genetic Non-Discrimination Act (SC 2017, c.3). https://www.canlii.org/en/ca/scc/doc/2020/2020scc17/2020scc17.html
11. National Tay-Sachs & Allied Diseases Association (NTSAD). Tay-Sachs Disease — Disease Information. https://www.ntsad.org/index.php/the-diseases/tay-sachs
12. NORD (National Organization for Rare Disorders). Tay-Sachs Disease — NORD Rare Disease Database. https://rarediseases.org/rare-diseases/tay-sachs-disease/

Last updated: 2026-07-26

Author: Yu Mizuno, non-physician research editor. This article aggregates 12 sources from peer-reviewed medical literature and public health agencies (tier 1=6 / tier 2=6), including NIH/MedlinePlus, NHGRI, OMIM, GeneReviews, ClinicalTrials.gov, ACOG, and ACMG guidelines.

This article is for educational purposes only and is not a substitute for medical advice from a licensed physician, board-certified medical geneticist, or board-certified genetic counselor. In emergencies, call 911 (US/Canada) or 119 (Japan).

Related: Genetic Diseases category

🇯🇵 For readers in Japan — a separate Japanese edition written for Japan’s healthcare system (not a translation): https://genelumen.com/ja/ja-neurogenetic/tay-sachs-hexa-carrier-inheritance-japan